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S U M M A R Y
To evaluate the immunotoxic effects of xenobiotics, we have established the Multi-ImmunoTox assay, in which
three stable reporter cell lines are used to evaluate the effects of chemicals on the IL-2, IFN-γ, IL-1β and IL-8
promoters. Here, we report the official validation study of the IL-2 luciferase assay (IL-2 Luc assay). In the Phase I
study that evaluated five coded chemicals in three sets of experiments, the average within-laboratory re-
producibility was 86.7%. In the Phase II study, 20 coded chemicals were evaluated at multiple laboratories. In
the combined results of the Phase I and II studies, the between-laboratory reproducibility was 80.0%. These
results suggested that the IL-2 Luc assay was reproducible both between and within laboratories. To determine
the predictivity, we collected immunotoxicological information and constructed the reference data by classifying
the chemical into immunotoxic compounds targeting T cells or others according to previously reported criteria.
When compared with the reference data, the average predictivity of the Phase I and II studies was 75.0%, while
that of additional 60 chemicals examined by the lead laboratory was 82.5%. Although the IL-2 Luc assay alone is
not sufficient to predict immunotoxicity, it will be a useful tool when combined with other immune tests.
1. Introduction
A well-functioning immune system is essential for maintaining the
integrity of an organism. Immune dysregulation can have serious ad-
verse health consequences, ranging from reduced resistance to infection
and neoplasia to allergic and autoimmune conditions. Environmental
contaminants, food additives, and drugs can target the immune system,
resulting in immune dysregulation. Accordingly, the potential for im-
munotoxicity, which is defined as the toxicological effects of xenobio-
tics on the function of the immune system, has raised serious concerns
from the public as well as from regulatory agencies. Currently, the as-
sessment of chemical immunotoxicity relies mainly on animal models
and in vivo assays, or ex vivo assays using cells from animals, to char-
acterize immunosuppression and sensitization. However, animal stu-
dies have many drawbacks, such as high cost, ethical concerns, and
questionable relevance to risk assessment for humans.
A worldwide vision is currently promoting alternative testing
methods and assessment strategies to reduce the use of laboratory an-
imals and, if possible, replace animals used in scientific studies (Adler
et al., 2011). The workshop hosted by the European Centre for the
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Validation of Alternative Methods (ECVAM) in 2003 focused on state-
of-the-art in vitro systems for evaluating immunotoxicity (Galbiati et al.,
2010; Gennari et al., 2005; Lankveld et al., 2010). A tiered approach
was proposed during the ECVAM workshop. Since useful information
can be obtained from regular 28-day general toxicity tests, the proposed
tiered approach would begin pre-screening for direct immunotoxicity
by evaluating myelotoxicity, as compounds capable of damaging or
destroying bone marrow will likely have immunotoxic effects (Lankveld
et al., 2010). If compounds are not myelotoxic, they are tested for
leukotoxicity. Compounds are then tested for immunotoxicity using
various approaches, such as the T cell–dependent antibody response,
lymphocyte proliferation assay, mixed lymphocyte reaction, NK cell
assay, dendritic cell maturation assay, human whole-blood cytokine
release assay (HWBCRA), and/or fluorescent cell chip (FCP) assay.
Several regulatory guidance or guidelines in immunotoxicology
have been published for the pharmaceutical industry and chemical
manufacturers. A workshop hosted by the International Life Sciences
Institute-Health and Environmental Sciences Institute (ILSI-HESI) was
held to share perspectives on immunotoxicity testing, developmental
immunotoxicity and integrated and alternative approaches to im-
munotoxicity testing. The workshop summarized that standard toxicity
studies, combined with triggered-based functional immune testing ap-
proaches, represent an effective approach to evaluate immunotoxic
potential (Boverhof et al., 2014).
Our group established the Multi-ImmunoTox assay (MITA) to evaluate
the effects of chemicals on the IL-2, IFN-γ, IL-1β, and IL-8 promoters using
three stable reporter cell lines (Kimura et al., 2014, 2018). Of these cell
lines, 2H4 derived from Jurkat cells contains stable luciferase green (SLG)
regulated by the IL-2 promoter, stable luciferase orange (SLO) regulated by
the IFN-γ promoter, and stable luciferase red (SLR) regulated by the G3PDH
promoter (Saito et al., 2011). The IL-2 luciferase assay (IL-2 Luc assay) uses
2H4 cells to identify the effects of chemicals on the IL-2 and IFN-γ pro-
moters in the presence of the stimulants phorbol 12-myristate 13-acetate
(PMA) and ionomycin (Io).
IL-2 exerts pleiotropic actions on CD4+ T cell differentiation via its
modulation of cytokine receptor expression. IL-2 promotes Th1 differ-
entiation by inducing IL-12Rb2 (and IL-12Rb1), promotes Th2 differentia-
tion by inducing IL-4Ra, inhibits Th17 differentiation by inhibiting gp130
(and IL-6Ra), and drives Treg differentiation by inducing IL-2Ra. IL-2 also
potently represses IL-7Ra, which decreases survival signals that normally
promote cell survival and memory cell development (reviewed by Liao et al.
(2011)). It is therefore conceivable that chemicals that affect IL-2 release by
T cells can significantly impact immune function.
Although our final goal is to officially validate the MITA as a defined
approach for the in vitro assessment of immunotoxicity, in the current
study we conducted a validation study for the IL-2 Luc assay. This va-
lidation study was conducted by a validation management team (VMT)
composed of the lead laboratory, three independent laboratories, and
four international expert members coordinated by the Japanese Center
for the Validation of Alternative Methods (JaCVAM). This validation
study examined the within- and between-laboratory reproducibility of
this assay. In addition, it shed light on the difficulty in determining the
predictivity of in vitro immunotoxicity tests because of the lack of re-
ference data regarding the targeted effects of immunotoxic chemicals.
In this study, we also proposed a procedure to create the reference data
for assessing chemical immunotoxicity.
2. Materials and methods
2.1. The 2H4 IL-2 reporter cell line
We used the previously established 2H4 reporter cell line derived from a
specific cell line of Jurkat cells with the ability to produce IL-2, kindly
provided by Professor Kazuo Sugamura, Department of Microbiology,
Tohoku University School of Medicine. 2H4 cells contain SLG regulated by
the IL-2 promoter, SLO regulated by the IFN-γ promoter, and SLR regulated
by the G3PDH promoter (Saito et al., 2011). This cell line was cultured in
RPMI-1640 (Sigma-Aldrich, St. Louis, MO) containing Antibiotic-Anti-
mycotic (Invitrogen) and 10% Hyclone™ fetal calf serum (Thermo Fisher
Scientific, Waltham, MA) (Jurkat growth medium) at 37 °C with 5% CO2.
2.2. Chemical treatment of 2H4 cells and measurement of luciferase activity
Based on previous reports (Kimura et al., 2014; Saito et al., 2011),
2H4 cells (2 × 105 cells/50 μl/well) in 96-well black plates (Greiner
Bio-One GmbH, Frickenhausen, Germany) were pretreated with dif-
ferent concentrations of individual chemicals for 1 h. The 2H4 cells
were then stimulated with 25 nM PMA and 1 μM ionomycin (PMA/Io)
for 6 h. Three luciferase activities (SLG luciferase activity (SLG-LA),
SLO luciferase activity (SLO-LA), and SLR luciferase activity (SLR-LA))
were simultaneously determined using a microplate-type luminometer
with a multi-color detection system (Phelios; Atto Co., Tokyo, Japan)
and Tripluc luciferase assay reagent (TOYOBO Co., Ltd., Osaka, Japan)
according to the manufacturers' instructions. Use of the 2H4 cell line
enabled measurement of SLG-LA driven by the IL-2 promoter (IL2LA),
SLO-LA driven by the INF-γ promoter (IFNLA), and SLR-LA driven by
G3PDH (GAPLA) in 2H4 cells. In this study we used just the IL2LA and
GAPLA. We accounted for variation in cell number and cell viability
after chemical treatment by normalizing the data for IL2LA (nIL2LA) or
IFNLA (nIFNLA) by dividing IL2LA or IFNLA, respectively, with GAPLA
in the 2H4 cells. In addition, we calculated % suppression, % aug-
mentation, and Inh-GAPLA as follows:
Inh-GAPLA= GAPLA of 2H4 cells treated with chemicals/GAPLA of
untreated cells. Definitions of these terms are provided in Table 1.
Table 1
The definition of the parameters in the IL-2 Luc assay.
Abbreviations Definition
GAPLA SLR luciferase activity reflecting GAPDH promoter activity
IL2LA SLO luciferase activity reflecting IL-2 promoter activity of 2H4 cells
nIL2LA IL2LA/GAPLA of 2H4 cells
% suppression (nIL2LA of 2H4 cells treated with chemicals/ nIL2LA of non-treated 2H4 cells) × 100
% augmentation (1-(nIL2LA of 2H4 cells treated with chemicals/ nIL2LA of non-treated 2H4 cells)) × 100
CV05 The lowest concentration of the chemical at which Inh-GAPLA becomes < 0.05.
Inh-GAPLA GAPLA of 2H4 cells treated with chemicals /GAPLA of untreated cells.
= ×%suppression (nIL2LA of 2H4 cells treated with chemicals/nIL2LA of non treated 2H4 cells) 100;
= ×%augmentation (1 (nIL2LA of 2H4 cells treated with chemicals/nIL2LA of non treated 2H4 cells)) 100;
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2.3. Validation studies
In the pre-validation study, transferability of this assay was ex-
amined using five non-coded chemicals (2-aminoanthracene, citral,
chloroquine diphosphate salt, dexamethasone and methylmercury(II)
chloride) in four test facilities, including the lead laboratory. These
chemicals were selected by the Chemical Selection Committee (CSC).
In the Phase I study, within- and between-laboratory reproducibility
of this assay was examined using five coded chemicals in three test
facilities. In the Phase II study, between-laboratory reproducibility was
examined using 20 coded chemicals in three test facilities. These che-
micals were selected by the CSC in the VMT based on the in-house
dataset of the lead laboratory and published papers on in vivo or in vitro
immunotoxicity tests. The chemicals were coded by JaCVAM as shown
in Appendix Tables 1 and 2, and distributed to the test facilities. The
study was conducted based on the Multi-ImmunoTox Assay protocol
Ver. 011E (Appendix 1).
2.4. Criteria for judgment of chemicals
A positive control examining the induction of nIFNLA in 2H4 cells
treated with PMA/Io and measurement of nIFNLA in non-treated 2H4
cells was required for each set of experiments. The fold induction of
nIFNLA of PMA/Ionomycin wells without chemicals (= (nIFNLA of
2H4 cells treated with PMA/Ionomycin)/(nIFNLA of non-treated 2H4
cells)) was calculated. If the fold induction for the positive control was
less than 3.0, the results obtained from the experiments were rejected.
Experiments for each chemical were repeated until two consistent
suppressive (or stimulatory) results or two consistent “no effect results”
were obtained. When two consistent results were obtained, the che-
micals were classified as indicated by the consistent results according to
three criteria. Chemicals which met the following three criteria were
judged as positive:
1. The mean % suppression was ≥35 (suppressive) or ≤−35 (stimu-
latory) with statistical significance. The statistical significance was
judged by its 95% confidence interval.
2. The result showed two or more consecutive suppressive (stimula-
tory) data points with statistical significance or one suppressive
(stimulatory) data point with statistical significance and a trend in
which at least three consecutive data points increase (or decrease) in
a dose-dependent manner. In the latter case, the trend can cross 0, as
long as only one data point shows the opposite effect without sta-
tistical significance.
3. Only data obtained at the concentration at which Inh-GAPLA is
≥0.05 contribute to the classification of the chemical.
If the three criteria are not met, the chemical would be classified as
having ‘no effect’.
It is important to recognize that IL-2 exerts pleiotropic actions on
CD4+ T cell differentiation via its modulation of cytokine receptor
expression. Indeed, IL-2 promotes Th1 and Th2 differentiation, while it
also drives Treg differentiation. These findings suggest that the aug-
mentation of IL-2 transcription can lead to either immunostimulation or
immunosuppression, depending on the surrounding tissue environment
in vivo. Therefore, if the results in our assay indicated either augmen-
tation or suppression, the chemical was considered as positive (P) and if
not, was classified as having “no effect” (N).
2.5. The performance of the IL-2 Luc assay
To determine the performance of the IL-2 Luc assay, it is crucial to
understand the immunotoxicological characteristics of the chemicals
used in the validation. Since the IL-2 Luc assay evaluates IL-2 tran-
scription by T cells, we attempted to classify the chemicals into two
categories: (i) immunotoxic chemicals which target T cells (TTCs), in-
cluding chemicals that directly affect T cell viability, T cell proliferation
or T cell function and (ii) others (NTTCs), which included chemicals
that were suggested to not directly affect T cell viability, T cell pro-
liferation or T cell function. To define those chemicals that TTCs, we
conducted a literature review focused on the available immunotoxicity
data and the following endpoints:
1. Decreased thymus weight.
2. Increased or decreased IL-2, IFN-γ, or IL-4 mRNA expression or
production by T cells ex vivo.
3. Increased or decreased IL-2, IFN-γ, or IL-4 mRNA expression or
production by T cells in vitro.
4. Suppressed T cell proliferation.
5. Suppressed cytotoxic T cell response.
6. Other data that clearly indicated that one of the immunotoxic me-
chanisms of the chemical was attributed to an effect on T cells.
Then, according to the rationale for classifying immunotoxic che-
micals reported by Luster et al. (1992b), we defined TTCs as chemicals
that satisfied one of the following criteria and then constructed a re-
ference database defining the immunotoxicities of the chemicals.
Criterion 1. Decreased thymus weight with additional one or more
findings among endpoints 2 to 5.
Criterion 2. Increased or decreased mRNA expression or protein
production in one or more cytokines in Endpoints 2 or 3 in multiple
reports.
Criterion 3. Increased or decreased mRNA expression or protein
production in two or more cytokines in Endpoints 2 or 3.
Criterion 4. The presence data suggesting that one of the im-
munotoxic mechanisms of the chemical was attributed to an effect on T
cells in Endopoint 6.
Then, by comparing the results of the IL-2 Luc assay (positive or no
effect) with the classification of the chemicals (TTC or NTTC), we cal-
culated the accuracy, sensitivity and specificity of the IL-2 Luc assay in
the validation study.
To classify the 25 chemicals used in the Phase I and II studies, we
used the chemical information kindly provided by the National
Toxicology Program (NTP) (Appendix 2). The reference database in-
cluding the immunotoxicological characteristics of each chemical is
shown in Appendix Table 3. The list of references is in Appendix 3.
2.6. Acceptance criteria
The within-laboratory reproducibility for all the test facilities was
conducted by an independent biostatistical analysis using five coded
chemicals and was overseen by the VMT. Based on the tentative ac-
ceptance criteria for the Phase I study, the concordance within la-
boratories was required to be greater than or equal to 80%. Twenty-five
coded test items were selected to confirm between-laboratory re-
producibility in the Phase I and II studies. At the end of testing, the test
facilities submitted a QC-certified copy of the entire study dossier to the
trial coordinator (study plan adhering to GLP principles, raw data, re-
cords, data analysis, and study report adhering to GLP principles).
Based on the tentative acceptance criteria for the Phase I and II studies,
the concordance for between-laboratory reproducibility was required to
be greater than or equal to 80%.
2.7. IL-2 Luc assay dataset for 60 chemicals and for chemicals evaluated by
the NTP
Based on the IL-2 Luc assay protocol (version 011E) and the criteria
used in the validation study, the lead laboratory reevaluated the data
for 60 chemicals reported previously (Kimura et al., 2018) and 31
chemicals of the 51 chemicals evaluated by the NTP (Luster et al.,
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1992b). Information regarding the immunotoxicity of these
chemicals is summarized in Appendix Table 4. The list of references is
in Appendix 4.
3. Results
3.1. Phase 0 study (technical transfer)
The preliminary test trial (Phase 0) was performed by the partici-
pating laboratories following the Multi-ImmunoTox Assay protocol Ver.
008.1E established by the lead laboratory, Tohoku University. Four
laboratories participated in the Phase 0 study of the IL-2 Luc assay using
the five open labeled chemicals 2-aminoantracene, citral, chloroquine
diphosphate salt, dexamethasone and methylmercury(II) chloride, and
conducted one analysis set (three experiments) for each chemical. The
response patterns of the five chemicals were similar among the four
laboratories. Based on the results, the VMT judged that technical and
protocol transfer of the IL-2 Luc assay was acceptable. After the Phase 0
study, the protocol was modified to optimize assay performance, and
refine the acceptance criteria and statistical analyses.
3.2. Phase I study (for within- and between-laboratory reproducibility and
predictivity)
For the Phase I study, a total of five coded chemicals (four T cell
targeting and one non-T cell targeting) were evaluated in three ex-
perimental sets consisting of three or more individual experiments for
each chemicals using the Multi-ImmunoTox Assay protocol Ver. 011E
established by the lead laboratory, Tohoku University.
The complete results of the Phase I study are shown in Table 2. The
within-laboratory reproducibility was 80.0% (4/5), 100% (5/5), and
80.0% (4/5) in Lab. A, Lab. B, and Lab. C, respectively. The average was
86.7% (13/15). The between-laboratory reproducibility was 80.0% (4/
5).
3.3. Phase II study (for between-laboratory reproducibility and predictivity)
The Phase II study for between-laboratory reproducibility and pre-
dictivity was conducted with a total of 20 coded chemicals (twelve T
cell targeting, seven non-T cell targeting and one undetermined) eval-
uated in one experimental set using the Multi-ImmunoTox Assay pro-
tocol Ver. 011E. The complete results of the Phase II study are shown in
Table 3. The between-laboratory reproducibility was 80% (16/20). To
further evaluate the between laboratory reproducibility, all of the re-
sults from Phases I and II were combined. The reproducibility for the
combined results was 80% (20/25), similar to that of the Phase II study
alone (Table 4).
3.4. The predictivity of the IL-2 Luc assay in the validation studies, in the
dataset composed of 60 chemicals, and in the evaluation of 31 chemicals
from the NTP database
To examine the predictivity of the IL-2 Luc assay, we surveyed the
literature for available in vivo, ex vivo, in vitro and mechanistic data on
the immunotoxicity of the chemicals used in this study (Appendix 3 and
4). The in vivo data may include alterations in the weight of immune
system organs such as spleen and thymus, delayed type hypersensitivity
response (DTH), and the susceptibility to infection and resistance to
transplanted tumors. The ex vivo data contain the effects of chemicals
on cytokine production, T cell-dependent antibody response in vitro, as
well as cytotoxic T cell response, mixed lymphocyte reaction, and T cell
mitogen-induced proliferation using immune cells from animals treated
with the chemicals in vivo. The in vitro data demonstrated the effects of
the chemicals on cytokine production or on T cell proliferation after
mitogen stimulation using cells or tissues from non-treated animals.
Using this information, we determined whether or not the chemicals
TTCs by affecting T cell viability, proliferation or function, according to
the rationale reported by Luster et al. (1992b) for classifying im-
munotoxic chemicals. Based on these criteria, the chemicals used in this
validation study were classified as 16 TTCs, 8 NTTCs, and 1 chemical
could not be classified (Appendix Table 3). Then, by comparing the
results of the IL-2 Luc assay (positive or no effect) with the classification
Table 2
Results of the Phase I study.
Chemical CAS Set Lab. A Lab. B Lab. C Concordance T cell targeting Rationale
Dibutyl phthalate 84-74-2 1st P P P 1 Yes 3, 4
2nd P P P
3rd P P P
Hydrocortisone 50-23-7 1st P P P 0 Yes 1
2nd N P P
3rd N P N
Lead(II) acetate 6080-56-4 1st P P P 1 Yes 1
2nd P P P
3rd P P P
Nickel(II) sulfate 10101-97-0 1st P P P 1 Yes 1
2nd P P P
3rd P P P
Zinc dimethyldithiocarbamate (DMDTC) 137-30-4 1st N N N 1 No
2nd N N N
3rd N N N
Within-laboratory reproducibility (%) 80.0 (4/5) 100 (5/5) 80.0 (4/5)
Average
86.7 (13/15)
Between-laboratory reproducibility (%) (Based on Majority) 80 (4/5)
Sensitivity (%) (Based on Majority) 75.0 (3/4) 100 (4/4) 100 (4/4)
Average
91.7 (11/12)
Specificity (%) (Based on Majority) 100 (1/1) 100 (1/1) 100 (1/1)
100 (3/3)
Accuracy (%) (Based on Majority) 80.0 (4/5) 100 (5/5) 100 (5/5)
Average
93.3 (14/15)
P: Positive, N: No effect.
Y. Kimura, et al. Toxicology in Vitro 66 (2020) 104832
4
of the chemicals (TTC or NTTC), we calculated the accuracy, sensitivity
and specificity of the IL-2 Luc assay in the validation study.
In the Phase I study (Table 2), the accuracy was 80.0% (4/5), 100%
(5/5), and 100% (5/5) in Lab. A, Lab. B, and Lab. C, respectively. The
average was 93.3% (14/15). The sensitivity and specificity were 91.7%
(11/12) and 100% (3/3), respectively.
In the Phase II study (Table 3), the accuracy was 73.7 (14/19),
68.4% (13/19), and 68.4% (13/19) in Lab. A, Lab. B, and Lab. C, re-
spectively. The average was 70.2% (40/57). The sensitivity was 75.0%
(9/12), 66.7% (8/12), and 66.7% (8/12) in Lab. A, Lab. B, and Lab. C,
respectively. The average was 69.4% (25/36). The specificity was
71.4% (5/7), 71.4% (5/7), and 71.4% (5/7) in Lab. A, Lab. B, and Lab.
C, respectively. The average was 71.4% (15/21).
In the combined results of the Phase I and Phase II studies (Table 4),
the accuracy was 75.0% (18/24), 75.0% (18/24), and 75.0% (18/24) in
Lab. A, Lab. B, and Lab. C, respectively. The average was 75.0% (54/
72). The sensitivity was 75.0% (12/16), 75.0% (12/16), and 75.0%
(12/16) in Lab. A, Lab. B, and Lab. C, respectively. The average 75.0%
(36/48). The specificity was 75.0% (6/8), 75.0% (6/8), and 75.0% (6/
8) in Lab. A, Lab. B, and Lab. C, respectively. The average was 75.0%
(18/24).
In addition, the lead laboratory reevaluated the data for the 60
chemicals reported previously (Kimura et al., 2018) by the same criteria
used in the validation study. The classification of the 60 chemicals and
their immunotoxicological information are summarized in Appendix
Table 4. The chemicals were classified as 34 TTCs, 6 NTTCs, and 20
chemicals that lacked sufficient information to classify their im-
munotoxic activity. The performance of the IL-2 Luc assay examining
these 60 chemicals for sensitivity, specificity and accuracy was 82.4%
(28/34), 83.3% (5/6), and 82.5% (33/40), respectively.
The lead laboratory also examined 31 of the 51 chemicals evaluated
by Luster et al. (1992b) and thus we compared the results of the IL-2
Luc assay with their classification of immunotoxic chemicals in Ap-
pendix Table 5. Although the results were preliminary because of the
limited number of chemicals used, the sensitivity, specificity and ac-
curacy of the IL-2 Luc assay for these chemicals was 59.1% (13/22),
44.4% (4/9), and 54.8% (17/31) (Table 5).
4. Discussion
We examined within-laboratory reproducibility in the Phase I study.
Lab. A, Lab. B, and Lab. C demonstrated 80%, 100%, and 80% re-
producibility, respectively. On the other hand, Lab. A, Lab. B, and Lab.
C demonstrated 80% between-laboratory reproducibility in the com-
bined data of the Phase I and Phase II studies. These results satisfied the
acceptance criteria for the validation study with a within-laboratory
reproducibility of at least 80% and a between-laboratory reproduci-
bility of at least 80%.
Table 3
Results of the Phase II study.
Chemical CAS Lab.A Lab.B Lab.C Concordance T cell targeting Rationale
2,4-Diaminotoluene 95-80-7 N N N 1 No
Benzo(a)pyrene 50-32-8 P P P 1 Yes 2), 3)
Cadmium chloride 10108-64-2 N N N 1 Yes 2), 3)
Dibromoacetic acid 631-64-1 P P N 0 Yes 1), 4)
Diethylstilbestol 56-53-1 P P P 1 Yes 1), 2), 4)
Diphenylhydantoin 630-93-3 N N N 1 Yes 2), 3), 4)
Ethylene dibromide 106-93-4 N N N 1 Yes 1)
Glycidol 556-52-5 P P P 1 No
Indomethacin 53-86-1 P P P 1 Yes 3), 4)
Isonicotinic acid Hydrazide 54-85-3 P N P 0 Yes 2)
Nitrobenzene 98-95-3 N P N 0 Undetermined
Urethane, Ethyl carbamate 51-79-6 P P P 1 Yes 1)
Tributyltin chloride 1461-22-9 P P P 1 Yes 1)
Perfluorooctanoic acid 335-67-1 P P P 1 Yes 1)
Dichloracetic acid 79-43-6 P P P 1 Yes 2), 3)
Toluene 108-88-3 N N N 1 No
Acetonitril 75-05-8 N N N 1 No
Mannitol 69-65-8 N N N 1 No
Vanadium pentoxide 1314-62-1 N N N 1 No
o-Benzyl-p-chorolophenol 120-32-1 P P P 1 No
Between-laboratory reproducibility (%) 80 (16/20)
Sensitivity (%) 75.0 (9/12) 66.7 (8/12) 66.7 (8/12)
Specificity (%) 71.4 (5/7) 71.4 (5/7) 71.4 (5/7)
Accuracy (%) 73.7 (14/19) 68.4 (13/19) 68.4 (13/19)
P: Positive, N: No effect.
Table 4
The combined results of the Phase I and Phase II studies.
Within-laboratory reproducibilities (%) 80 (4/5) 100 (5/5) 80 (4/5)
Average
86.7 (13/15)
Between-laboratory reproducibilities (%) (Based on majority for Phase I) 80 (20/25)
Sensitivity (%) 75.0 (12/16) 75.0 (12/16) 75.0 (12/16)
Average
75.0 (36/48)
Specificity (%) 75.0 (6/8) 75.0 (6/8) 75.0 (6/8)
Average
75.0 (18/24)
Accuracy (%) 75.0 (18/24) 75.0 (18/24) 75.0 (18/24)
Average
75.0 (54/72)
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Table 5
Data set for the IL-2 Luc assay.
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Reference data that indicate which chemicals are immunotoxic are
indispensable for determining the performance of the IL-2 Luc assay.
However, such reference data are lacking for most chemicals and thus
we attempted to create reference data for the chemicals used in this
study. Although there is no gold standard to date for identifying im-
munotoxic chemicals, Luster et al. (1992b) proposed a rationale for
classifying immunotoxicants based on their ability to produce a sig-
nificant dose-response effect in a single immune test or significantly
alter two or more test results at the highest dose of the chemical tested.
They classified chemicals based on the results obtained in immune tests
according to this rationale and found a significant correlation between
the judgment of immunotoxic chemicals and host resistance (Luster
et al., 1993). Therefore, we used this rationale and classified chemicals
based on the immunotoxicological information for each chemical
published previously
Then, by comparing the results of the IL-2 Luc assay (positive or no
effect) with the reference database we created, we calculated the per-
formance of the IL-2 Luc assay. The average of the accuracy of the
combined results of the Phase I and Phase II studies was 75.0% (54/72),
while the accuracy obtained using the 60 chemicals was 82.5% (33/40).
In our previous study in which only immunosuppressive drugs
whose effects on human have been well established were examined by
the IL-2 Luc assay (Kimura et al., 2014), we demonstrated that tacro-
limus (TAC), cyclosporine A (CyA) and dexamethasone (Dex) sig-
nificantly suppressed IL-2 luciferase activity (IL-2 LA), although the
average Lowest Observed Effect Levels (LOELs) of TAC and CyA were
significantly lower that of DEX. The off-label immunosuppressive drugs
chloroquine, minocycline, dapsone, and colchicine significantly sup-
pressed IL-2 LA. The anti-cancer drugs actinomycin D and cisplatin and
a representative immunosuppressive drug, azathioprine, also sig-
nificantly suppressed IL-2 LA. No suppressive effects on IL-2 LA were
demonstrated by several immunosuppressants whose mechanism of
action is dependent on the inhibition of DNA synthesis or anti-pro-
liferative effects on T cells, such as rapamycin, mizoribine, cyclopho-
sphamide, methotrexate and mycophenolic acid. These data suggest
that IL-2 LA is an assay most suitable to detect chemicals that affect
cytokine production.
The HWBCRA, previously examined in a rigorous prevalidation ef-
fort by ECVAM and other groups, is an immune test to examine the
effects of chemicals on IL-4 or IL-1β production stimulated by staphy-
lococcal enterotoxin B (SEB) or LPS, respectively (Langezaal et al.,
2001, 2002). This assay uses human whole blood cells and examines the
production of IL-4 by T cells and of IL-1β by monocytes. This concept is
similar to that of the MITA, in which the effects of chemicals on T cells
and monocytes are examined using Jurkat cell-derived 2H4 and THP-1-
derived THP-G1b cells. Interestingly, the evaluation of chemicals by IL-
4 production in the HWBCRA was almost identical to the results of the
IL-2 Luc assay: both detected strong immunosuppression by TAC, CyA,
DEX and actinomycin D, which are more potent than chloroquine and
azathioprine. The cardiac glycoside digoxin is classified as an im-
munotoxic chemical by both assays. Cyclophosphamide and mizoribine
require metabolic activation and thus are not judged as im-
munosuppressive in either assay. In addition, the HWBCRA is also
considered to be unsuitable for detecting immunotoxic chemicals
whose effects are dependent on suppressing cell proliferation.
The ability to similarly detect known immunosuppressive chemicals
suggests that the IL-2 Luc assay may be a useful alternative to the
HWBCRA for examining the effects of chemicals on T cells. In addition,
the IL-2 Luc assay has a number of advantages over the HWBCRA, in-
cluding: 1) The IL-2 Luc assay does not require primary cells, 2) it does
not require cytokine quantification using ELISA, and 3) the time
required for the IL-2 Luc assay is less than 8 h. However, similar to the
HWBCRA, the IL-2 Luc assay cannot detect immunosuppression in
chemicals whose effects depend on the suppression of cell proliferation
or require metabolic activation. Therefore, these chemicals are con-
sidered as those out of applicability domain.
Luster et al. (1988) proposed a screening battery using a ‘tier’ ap-
proach for detecting potential immunotoxic compounds in mice. Then,
they defined criteria to classify immunotoxic chemicals using several
parameters comprising the ‘tier approach’ and classified 51 chemicals
into immunotoxic and non-immunotoxic compounds (Luster et al.,
1992b). Furthermore, they examined the ability of various immune
tests to predict increased susceptibility for a number of models of dis-
ease resistance (Luster et al., 1992a). Their final results demonstrated
that: 1) A number of the immune tests provided a relatively high as-
sociation with changes in host resistance (i.e., > 70%) such as IgM
plaque forming cell (PFC) response to sheep red blood cells, T cell
mitogen response, DTH, surface markers, and spleen cellularity. In
contrast, several of the tests, such as leukocyte counts and lympho-
proliferative response to lipopolysaccharide (LPS) were poor predictors,
with concordance values of approximately 50%. 2) The combination of
two immune tests compared with the host resistance classification in-
creased the concordance from that obtained using individual tests. Pair-
wise combinations which included either the PFC response, surface
markers, or DHRs gave consistently higher concordances.
When the IL-2 Luc assay examined 31 of the 51 chemicals evaluated
by Luster et al. (1992b), its performance was similar to that of mixed
lymphocyte reaction (MLR), DHR, and spleen cellularity and better
than leukocyte counts or LPS response. Moreover, among 7 chemicals
judged as false negative by the IL-2 Luc assay, 5 chemicals was judged
as positive by Luster et al. (1992b) based on their suppressive effects on
T cell mitogen response. Since our previous study demonstrated the
inability of the IL-2 Luc assay to detect immunosuppressive effects of
chemicals which are dependent on their suppressive effects on T cell
proliferation, these 5 chemicals are out of applicability domain. Taking
this into account, the sensitivity, specificity and accuracy of the IL-2 Luc
assay was 76.5% (13/17), 44.4% (4/9), and 65.4% (17/26).
Thus, we would like to propose the MITA for in vitro testing to detect
immunotoxic chemicals in future. The MITA can evaluate the effects of
chemicals on IL-2, IFN-γ, IL-1β and IL-8 promoter activities. The in-
duction of these cytokines is mediated by a wide range of signaling
pathways, including as a minimum the MAP kinase, NF-kB, and cal-
cium/calmodulin pathways. It is also well known that the induction of
different immune-related molecules such as cytokines or chemokines
commonly uses at least one of these signaling pathways. Therefore,
although the MITA evaluates only the effects of chemicals on the
transcription of four cytokines, it may be able to assess the effects of
chemicals on a much wider range of immune responses. When com-
bined with other in vitro assays, such as assessment of myelotoxicity or
T cell mitogen responses, the predictivity of the MITA would be in-
creased. Furthermore, the combination of the MITA with the IL-8 Luc
assay (OECD442E) can evaluate the effects of chemicals on T cells and
macrophages, and the sensitizing potentials of chemicals. The data
obtained from these assays can be used by both industry and regulatory
agencies to assess the immunotoxicity risks of chemicals.
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TTC: Immunotoxic chemicals targeting T cells, NTTC (Others), Undetermined: Undetermined because of insufficient or inconsistent reported data, P: Positive, N: No
effect, Blue color: accurate, Red color: false, yellow color: cannot be judged by undetermined classification of chemicals.
#: The criterion number used to define immunotoxicity.
*: Cyclophosphamide needs metabolic activity to demonstrate the activity.
Y. Kimura, et al. Toxicology in Vitro 66 (2020) 104832
7
Acknowledgement
This validation study was supported by Grants-in-Aid from the
Ministry of Economy, Trade and Industry (METI), Japan, the Ministry of
Health, Labor and Welfare (MHLW), Japan, and the Japanese Society
for Alternatives to Animal Experiments (JSAAE), Japan. We gratefully
acknowledge the voluntary work by the participating laboratories, the
European Union Reference Laboratory for Alternatives to Animal
Testing (EURL-ECVAM), the NTP Interagency Center for the Evaluation
of Alternative Toxicological Methods (NICEATM), and the members of
the peer review panel, Henk van Loveren (Maastricht University), Haley
Neff-LaFord (Seattle Genetics, Inc.), Barbara Kaplan (Mississippi State
University), Sang-Hyun Kim (Kyungpook National University), Fujio
Kayama (Jichi Medical University), and Xingchao Geng (National
Center for Safety Evaluation of Drugs (NCSED).
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tiv.2020.104832.
References
Adler, S., Basketter, D., Creton, S., et al., 2011. Alternative (non-animal) methods for
cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 85,
367–485.
Boverhof, D.R., Ladics, G., Luebke, B., et al., 2014. Approaches and considerations for the
assessment of immunotoxicity for environmental chemicals: a workshop summary.
Regul. Toxicol. Pharmacol. 68, 96–107.
Galbiati, V., Mitjans, M., Corsini, E., 2010. Present and future of in vitro im-
munotoxicology in drug development. J. Immunotoxicol. 7, 255–267.
Gennari, A., Ban, M., Braun, A., et al., 2005. The use of in vitro systems for evaluating
immunotoxicity: the report and recommendations of an ECVAM workshop. J.
Immunotoxicol. 2, 61–83.
Kimura, Y., Fujimura, C., Ito, Y., et al., 2014. Evaluation of the multi-ImmunoTox assay
composed of 3 human cytokine reporter cells by examining immunological effects of
drugs. Toxicol. in Vitro 28, 759–768.
Kimura, Y., Fujimura, C., Ito, Y., et al., 2018. Profiling the immunotoxicity of chemicals
based on in vitro evaluation by a combination of the multi-ImmunoTox assay and the
IL-8 Luc assay. Arch. Toxicol. 92, 2043–2054.
Langezaal, I., Coecke, S., Hartung, T., 2001. Whole blood cytokine response as a measure
of immunotoxicity. Toxicol. In Vitro 15, 313–318.
Langezaal, I., Hoffmann, S., Hartung, T., et al., 2002. Evaluation and prevalidation of an
immunotoxicity test based on human whole-blood cytokine release. Alternat. Lab.
Anim. 30, 581–595.
Lankveld, D.P., Van Loveren, H., Baken, K.A., et al., 2010. In vitro testing for direct
immunotoxicity: state of the art. Methods Mol. Biol. 598, 401–423.
Liao, W., Lin, J.X., Wang, L., et al., 2011. Modulation of cytokine receptors by IL-2
broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12,
551–559.
Luster, M.I., Munson, A.E., Thomas, P.T., et al., 1988. Development of a testing battery to
assess chemical-induced immunotoxicity: National Toxicology Program’s guidelines
for immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 10, 2–19.
Luster, M.I., Pait, D.G., Portier, C., et al., 1992a. Qualitative and quantitative experi-
mental models to aid in risk assessment for immunotoxicology. Toxicol. Lett. 71–78
64-65 Spec No.
Luster, M.I., Portier, C., Pait, D.G., et al., 1992b. Risk assessment in immunotoxicology. I.
Sensitivity and predictability of immune tests. Fundam. Appl. Toxicol. 18, 200–210.
Luster, M.I., Portier, C., Pait, D.G., et al., 1993. Risk assessment in immunotoxicology. II.
Relationships between immune and host resistance tests. Fundam. Appl. Toxicol. 21,
71–82.
Saito, R., Hirakawa, S., Ohara, H., et al., 2011. Nickel differentially regulates NFAT and
NF-kappaB activation in T cell signaling. Toxicol. Appl. Pharmacol. 254, 245–255.
Y. Kimura, et al. Toxicology in Vitro 66 (2020) 104832
8
